GSK drops the development of engineered cell therapyThis development further places ONCY in a favourable position as pelareorep is able to remodel the tumor microenvironment and enhance T-cell clonality, and thus mitigating T-cell exhaustion, particularly when pelareorep is combined with an immune checkpoint inhibitor.
https://www.evaluate.com/vantage/articles/news/deals/gsk-deals-cell-therapy-another-setback